TATA Health Sells Loss-Making Subsidiary for HK$1 to Cut Liabilities

An update from TATA Health International Holdings Ltd. ( (HK:1255) ) is now available.

TATA Health International Holdings Ltd. has disposed of its entire interest in a loss-making subsidiary, referred to as the Target Company, for a token consideration of HK$1.00, with completion taking place on 13 March 2026. As a result, the Target Company has ceased to be a subsidiary, and its financially weak Target Group, which had unaudited consolidated net liabilities of about HK$4.1 million as of 31 December 2025, will no longer be consolidated into the group’s financial statements.

The buyer, an independent Hong Kong trading company that is already a lender to a related group entity and has existing commercial ties through a fellow subsidiary, acquired the shares after arm’s length negotiations. Classified under Hong Kong listing rules as a disclosable transaction because relevant percentage ratios exceed 5% but remain below 25%, the disposal reflects TATA Health’s effort to shed consistently loss-making operations and is expected to reduce ongoing operational and financial burdens without requiring shareholder approval.

More about TATA Health International Holdings Ltd.

TATA Health International Holdings Ltd. is a Cayman Islands–incorporated investment holding company listed in Hong Kong. Through its subsidiaries, the group operates businesses that include trading activities and related services, with a focus on managing and rationalising underperforming assets within its portfolio to improve overall financial health and operational efficiency.

Average Trading Volume: 125,647

Technical Sentiment Signal: Buy

Current Market Cap: HK$347.3M

See more insights into 1255 stock on TipRanks’ Stock Analysis page.